AGP Stock Overview
Manufactures, sells, wholesales, distributes, exports, imports, markets, deals in pharmaceutical and healthcare products under licensing arrangements in Pakistan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
AGP Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨130.85 |
| 52 Week High | PK₨135.93 |
| 52 Week Low | PK₨59.00 |
| Beta | 0.70 |
| 11 Month Change | 15.17% |
| 3 Month Change | 38.88% |
| 1 Year Change | 109.43% |
| 33 Year Change | 15.96% |
| 5 Year Change | 64.84% |
| Change since IPO | 55.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| AGP | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 1.3% | 7.4% | 0.3% |
| 1Y | 109.4% | 118.3% | 50.1% |
Return vs Industry: AGP underperformed the PK Pharmaceuticals industry which returned 127.6% over the past year.
Return vs Market: AGP exceeded the PK Market which returned 51% over the past year.
Price Volatility
| AGP volatility | |
|---|---|
| AGP Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in PK Market | 9.6% |
| 10% least volatile stocks in PK Market | 3.5% |
Stable Share Price: AGP has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: AGP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,574 | Muhammad Nasir | www.agp.com.pk |
AGP Limited manufactures, sells, wholesales, distributes, exports, imports, markets, deals in pharmaceutical and healthcare products under licensing arrangements in Pakistan. The company offers products in the areas of aminoglycosides, angiotensin II antagonist, anti epileptics, anti-gout, anti-infective antidiarrheal, anti-inflammatory enzyme, antidiarrheal microorganisms, antifibrinolytic, antihistamines systemic, antileuk anti-ashtm sys, antineoplastic agent, anti-obesity, antirheumatic non-steroid, antispasmodic and anticholinergic plain, atypical antipsychotics, biguanide and S-urea combs, bile stone therapy, calcium, calcium channel blocker, cephalosporins oral and inject, DPP-IV Inh and biguanide comb, DPP-IV Inh A-diab plain, expectorants, eye tonics and eye vitamins, fluoroquinolones, glitazone and S-urea combs, glitazone A-diabs plain, glitazone and biguanide combinations, hepatitis C antivirals, iron combination products, iron plain, lipid modifying agents combinations, menthae piperitae aetheroleum, muscle relaxants central, narcotic analgesic, and non-narcotic analgesic. It provides narcotic analgesic, non-narcotic analgesics, nucleoside reverse transcriptase inhibitors, Oth anti-anaem folic acid, other musculoskeletal products, other stomach disorder products, proton pump inhibitor, psycholeptic antidepressant, SGLT2 inhibitors antidiabetic and biguanide, sitagliptin, SSRI antidepressants, sulphonylurea, systemic vasoprotectives, tonic, topical antihaemorrhoidal, urinary anti-infectives, urinary incontinence prd, vitamin B12, vitamin B12 plain, vitamin C combinations, vitamin D3, and xanthine-systemic products.
AGP Limited Fundamentals Summary
| AGP fundamental statistics | |
|---|---|
| Market cap | PK₨36.64b |
| Earnings (TTM) | PK₨1.85b |
| Revenue (TTM) | PK₨21.24b |
19.8x
P/E Ratio1.7x
P/S RatioIs AGP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGP income statement (TTM) | |
|---|---|
| Revenue | PK₨21.24b |
| Cost of Revenue | PK₨10.11b |
| Gross Profit | PK₨11.14b |
| Other Expenses | PK₨9.29b |
| Earnings | PK₨1.85b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.61 |
| Gross Margin | 52.43% |
| Net Profit Margin | 8.71% |
| Debt/Equity Ratio | 38.7% |
How did AGP perform over the long term?
See historical performance and comparison